The completion of accelerated approval enrollment removes a key binary risk and sets a clear catalyst timeline (Q2 2027 topline data). However, the high cash burn and pre-revenue status mean the stock will trade on pipeline updates rather than financials. Monitor for full enrollment completion of PROACT 1 in H2 2026 and any partnering or financing announcements given the ~9-month cash runway buffer.
Price Chart
Executive Summary
ProKidney reported Q2 2026 financial results with no revenue or EPS guidance to analyze, as the company is pre-commercial. The key highlight is completing enrollment of ~320 patients for the PROACT 1 accelerated approval efficacy analysis, with topline eGFR slope results expected in Q2 2027 — a major derisking milestone. Cash burn continues, with $181.6 million in cash as of June 30, 2026, down from $224.9 million in Q1 2026, providing runway into mid-2027.
Key Financial Metrics
Key Facts
- Completed enrollment of ~320 patients for the PROACT 1 accelerated approval efficacy analysis
- Topline eGFR slope results anticipated in Q2 2027
- On track for full enrollment of ~470 patients in PROACT 1 in H2 2026
- Cash, cash equivalents, and marketable securities: $181.6 million at June 30, 2026 (vs $224.9 million at March 31, 2026)
- Net loss before noncontrolling interest: $46.4 million in Q2 2026 vs $37.0 million in Q2 2025
- Net loss per share available to Class A common stockholders: $(0.15) in Q2 2026 vs $(0.13) in Q2 2025
- R&D expenses increased to $36.1 million in Q2 2026 from $25.9 million in Q2 2025, driven by PROACT 1 study costs
- Appointed Kenneth Locke as Chief Technical Officer in June 2026
- 302,312,504 Class A and Class B common shares outstanding at June 30, 2026
Financial Impact
Cash burn rate of ~$43.3M per quarter (Q2 2026), with cash runway into mid-2027
Risk Factors
- Clinical trial failure (eGFR slope may not meet statistical significance in Q2 2027)
- Cash runway only into mid-2027 — likely needs additional financing before data readout
- High dilution: Class A shares outstanding increased from ~142M to ~206M since December 2025
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342213 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $1.61 $1.85 | ▲ +14.91% | ▲ +15.97% | $1.72 (+6.83%) |
Aug 10, 2026 7w ago | Press Release | $1.61 $1.85 | ▲ +14.91% | ▲ +15.97% | $1.72 (+6.83%) |
May 15, 2026 20w ago | 8-K | $1.66 $1.67 | ▲ +0.60% | ▼ −1.52% | $1.72 (+3.61%) |
May 15, 2026 20w ago | Press Release | $1.66 $1.67 | ▲ +0.60% | ▼ −1.52% | $1.72 (+3.61%) |
Apr 17, 2026 24w ago | DEFA14A | $2.10 $1.61 | ▼ −23.33% | ▼ −27.54% | $1.72 (−18.10%) |
Mar 18, 2026 28w ago | Press Release | $1.95 $2.18 | ▲ +11.79% | ▲ +4.17% | $1.72 (−11.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access